Halyna Pylypenko

3.8k citations

29 papers · 1.3k indexed · 1 hit paper · h-index 11

Impact in

Hematology top 1%
- Multiple Myeloma Research and Treatments
Genetics top 2%
- Chronic Lymphocytic Leukemia Research

Papers in ⓘ

Genetics 16
- Myeloproliferative Neoplasms: Diagnosis and Treatment 9
- Chronic Lymphocytic Leukemia Research 8
Oncology 14
- Cytokine Signaling Pathways and Interactions 4
- Viral-associated cancers and disorders 4

Co-authors: Sebastian Grosicki (12 shared papers)Helgi van de Velde (7 shared papers)Tadeusz Robak (7 shared papers)Xavier Leleu (6 shared papers)Philippe Moreau (3 shared papers)William Deraedt (3 shared papers)Bertrand Arnulf (2 shared papers)Jean‐Luc Harousseau (2 shared papers)
Journals: Blood (11 papers)Journal of Clinical Oncology (6 papers)Haematologica (3 papers)HemaSphere (2 papers)New England Journal of Medicine (1 paper)
Partner nations: Czechia Poland United States

In The Last Decade

Halyna Pylypenko

29 papers receiving 1.3k citations

Hit Papers

align trajectories log scale

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study 2011 · 661 citations

Peers

Countries citing papers authored by Halyna Pylypenko

Since Specialization

Citations

This map shows the geographic impact of Halyna Pylypenko's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Halyna Pylypenko with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Halyna Pylypenko more than expected).

Fields of papers citing papers by Halyna Pylypenko

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Halyna Pylypenko. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Halyna Pylypenko. The network helps show where Halyna Pylypenko may publish in the future.

Co-authors

The 25 scholars most cited alongside Halyna Pylypenko, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Halyna Pylypenko Line = papers co-authored together Halyna Pylypenko links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 29 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study The Lancet Oncology ·Philippe Moreau, Halyna Pylypenko, Sebastian Grosicki, Ievgenii Karamanesht, Xavier Leleu, Maria Grishunina, Grigoriy Rekhtman, Zvenyslava Masliak, Tadeusz Robak, A. V. Shubina, Bertrand Arnulf, Martin Kropff, James Cavet, Dixie‐Lee Esseltine, Huaibao Feng, Suzette Girgis, Helgi van de Velde, William Deraedt, Jean‐Luc Harousseau Hit paper breakdown →	2011	661
2	Bortezomib-Based Therapy for Newly Diagnosed Mantle-Cell Lymphoma New England Journal of Medicine ·Tadeusz Robak, Huiqiang Huang, Jie Jin, Jun Zhu, Ting Liu, Olga Samoilova, Halyna Pylypenko, Gregor Verhoef, Noppadol Siritanaratkul, Evgenii A. Osmanov, Julia Alexeeva, Juliana Pereira, Johannes Drach, Jiří Mayer, Xiaonan Hong, Rumiko Okamoto, Lixia Pei, Brendan Rooney, Helgi van de Velde, Franco Cavalli	2015	261
3	A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia Leukemia & lymphoma ·Thomas J. Kipps, Herbert Eradat, Sebastian Grosicki, John Catalano, Walter Cosolo, Iryna Dyagil, Sreeni Yalamanchili, Akiko Chai, Srikumar Sahasranaman, Elizabeth A. Punnoose, Deborah Hurst, Halyna Pylypenko	2015	151
4	Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma Haematologica ·Bertrand Arnulf, Halyna Pylypenko, Sebastian Grosicki, Ievgenii Karamanesht, Xavier Leleu, Helgi van de Velde, H. Feng, Andrew Cakana, William Deraedt, Philippe Moreau	2012	87
5	Final Results from PROUD-PV a Randomized Controlled Phase 3 Trial Comparing Ropeginterferon Alfa-2b to Hydroxyurea in Polycythemia Vera Patients Blood ·Heinz Gisslinger, Christoph Klade, Pencho Georgiev, Aleksander B. Skotnicki, Liana Gercheva, Miklós Egyed, Viktor Rossiev, Petr Ďulíček, Árpád Illés, Halyna Pylypenko, Liliya Sivcheva, Jiřı́ Mayer, Barbara Grohmann-Izay, Hans Carl Hasselbalch, Róbert Královics, Jean‐Jacques Kiladjian	2016	23
6	Weekly selinexor, bortezomib, and dexamethasone (SVd) versus twice weekly bortezomib and dexamethasone (Vd) in patients with multiple myeloma (MM) after one to three prior therapies: Initial results of the phase III BOSTON study. Journal of Clinical Oncology ·Meletios Α. Dimopoulos, Sosana Delimpasi, Maryana Simonova, Ivan Špıčka, Luděk Pour, Iryna Kryachok, Maria Gavriatopoulou, Halyna Pylypenko, Holger W. Auner, Xavier Leleu, Vadim Doronin, Polina Kaplan, Roman Hájek, Reuben Benjamin, Tuphan Kanti Dolai, Dinesh Kumar Sinha, Melina Arazy, Paul G. Richardson, Nizar J. Bahlis, Sebastian Grosicki	2020	22
7	A Phase 1, Open-Label Study of MGD013, a Bispecific DART® Molecule Binding PD-1 and LAG-3 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Blood ·Jie Wang, Adam S. Asch, Nada Hamad, Andrew Weickhardt, Monika Tomaszewska‐Kiecana, Monika Długosz‐Danecka, Halyna Pylypenko, Shakeela Bahadur, Susanna V. Ulahannan, Janine Koucheki, Jichao Sun, Hua Li, Francine Chen, Xiaoyu Zhang, John Muth, Patrick Kaminker, Paul A. Moore, Bradley Sumrow	2020	19
8	Ibrutinib combined with bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): First results from a randomized, double-blind, placebo-controlled, phase III study. Journal of Clinical Oncology ·Asher Chanan‐Khan, Paula Cramer, Fatih Demırkan, Graeme Fraser, Rodrigo Santucci Silva, Halyna Pylypenko, Sebastian Grosicki, Ann Janssens, Alexander Pristupa, Jiřı́ Mayer, Marie‐Sarah Dilhuydy, Javier Loscertales, Nancy L. Bartlett, Abraham Avigdor, Simon Rule, Steven Sun, Michelle Mahler, Mariya Salman, Angela Howes, Michael Hallek	2015	15
9	Evidence for Superior Efficacy and Disease Modification after Three Years of Prospective Randomized Controlled Treatment of Polycythemia Vera Patients with Ropeginterferon Alfa-2b Vs. HU/BAT Blood ·Heinz Gisslinger, Christoph Klade, Pencho Georgiev, Dorota Krochmalczyk, Liana Gercheva, Miklós Egyed, Viktor Rossiev, Petr Ďulíček, Árpád Illés, Halyna Pylypenko, Lylia Sivcheva, Jiřı́ Mayer, Vera Yablokova, Kurt Krejcy, Barbara Grohmann-Izay, Hans Carl Hasselbalch, Róbert Královics, Jean‐Jacques Kiladjian	2018	14
10	Safety and Efficacy of CD37-Targeting Naratuximab Emtansine PLUS Rituximab in Diffuse Large B-Cell Lymphoma and Other NON-Hodgkin'S B-Cell Lymphomas - a Phase 2 Study Blood ·Moshe Levy, Deepa Jagadeesh, Жанет Грудева-Попова, Marek Trněný, Wojciech Jurczak, Halyna Pylypenko, Marc André, Sunita D. Nasta, Dalit Rechavi-Robinson, Sara Toffanin, Sandrine Micallef, Antoine Attinger, Elisabeth Rouits, Marie-Claude Roubaudi-Fraschini, P. Orfanos, Mariola Dymkowska, Heidi Nauwelaerts, S. Woei-A-Jin	2021	11
11	Long-Term Use of Ropeginterferon Alpha-2b in Polycythemia Vera: 5-Year Results from a Randomized Controlled Study and Its Extension Blood ·Heinz Gisslinger, Christoph Klade, Pencho Georgiev, Dorota Krochmalczyk, Liana Gercheva, Miklós Egyed, Petr Ďulíček, Árpád Illés, Halyna Pylypenko, Lylia Sivcheva, Jiřı́ Mayer, Vera Yablokova, Kurt Krejcy, Victoria Empson, Hans Carl Hasselbalch, Róbert Královics, Jean‐Jacques Kiladjian	2020	10
12	Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study Leukemia & lymphoma ·Tadeusz Robak, Huiqiang Huang, Jie Jin, Jun Zhu, Ting Liu, Olga Samoilova, Halyna Pylypenko, Gregor Verhoef, Noppadol Siritanaratkul, Evgenii A. Osmanov, Juliana Pereira, Jiřı́ Mayer, Xiaonan Hong, Rumiko Okamoto, Lixia Pei, Brendan Rooney, Helgi van de Velde, Franco Cavalli	2017	9
13	Ibrutinib (I) plus bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): a 2-year follow-up of the HELIOS study. Journal of Clinical Oncology ·Graeme Fraser, Paula Cramer, Fatih Demırkan, Rodrigo Santucci Silva, Halyna Pylypenko, Sebastian Grosicki, Ann Janssens, Aleksander Pristupa, Jiřı́ Mayer, Marie‐Sarah Dilhuydy, Javier Loscertales, André Goy, Abraham Avigdor, Simon Rule, Charles E. Phelps, Michelle Mahler, Mariya Salman, Angela Howes, Sriram Balasubramanian, Asher Chanan‐Khan	2016	8
14	Preliminary Results of a Phase II Open-Label, Randomized Study of the BH3 Mimetic Protein Navitoclax (ABT-263) with or without Rituximab for Treatment of Previously Untreated B-Cell Chronic Lymphocytic Leukemia Blood ·Herbert Eradat, Sebastian Grosicki, John Catalono, Walter Cosolo, Iryna Dyagil, Thomas J. Kipps, Beiyao Zheng, Sreeni Yalamanchili, Srikumar Sahasranaman, Deborah Hurst, William Ho, Halyna Pylypenko	2012	7
15	Ropeginterferon Alfa-2b versus Standard Therapy for Polycythaemia Vera; a Randomised, Controlled, Phase III Trial SSRN Electronic Journal ·Heinz Gisslinger, Christoph Klade, Pencho Georgiev, Dorota Krochmalczyk, Liana Gercheva, Miklós Egyed, Viktor Rossiev, Petr Ďulíček, Árpád Illés, Halyna Pylypenko, Lylia Sivcheva, Jiřı́ Mayer, Vera Yablokova, Kurt Krejcy, Barbara Grohmann-Izay, Hans Carl Hasselbalch, Róbert Královics, Jean‐Jacques Kiladjian, PROUD-PV Study Group	2019	5
16	A Phase 3 Prospective Randomized International Study (MMY-3021) Comparing Subcutaneous and Intravenous Administration of Bortezomib In Patients with Relapsed Multiple Myeloma Blood ·Philippe Moreau, Halyna Pylypenko, Sebastian Grosicki, Е. Е. Караманешт, Xavier Leleu, Maria Grishunina, Grigoriy Rekhtman, Zvenyslava Masliak, Tadeusz Robak, A. V. Shubina, Jean‐Paul Fermand, Martin Kropff, James Cavet, Sudha Parasuraman, Huaibao Feng, Donna Skee, Helgi van de Velde, William Deraedt, Jean‐Luc Harousseau	2010	5
17	IBRUTINIB PLUS BENDAMUSTINE AND RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): 2-YEAR FOLLOW-UP INCLUDING MRD FROM THE HELIOS STUDY Haematologica ·Graeme Fraser, Paula Cramer, Fatih Demırkan, R Santucci Silva, Sebastian Grosicki, Ann Janssens, Jiřı́ Mayer, Marie‐Sarah Dilhuydy, Halyna Pylypenko, Javier Loscertales, André Goy, Abraham Avigdor, S. Rule, Charles E. Phelps, Michelle Mahler, Mariya Salman, Angela Howes, Michael Hallek	2016	4
18	Ropeginterferon Alfa‐2b: Efficacy and Safety in Different Age Groups HemaSphere ·Heinz Gisslinger, Christoph Klade, Pencho Georgiev, Dorota Krochmalczyk, Liana Gercheva, Miklós Egyed, Viktor Rossiev, Petr Ďulíček, Árpád Illés, Halyna Pylypenko, Lylia Sivcheva, Jiřı́ Mayer, Vera Yablokova, Kurt Krejcy, Hans Carl Hasselbalch, Róbert Královics, Jean‐Jacques Kiladjian, (unknown)	2020	4
19	Effects of refractory status to lenalidomide on safety and efficacy of selinexor, bortezomib, and dexamethasone (XVd) versus bortezomib and dexamethasone (Vd) in patients with previously treated multiple myeloma. Journal of Clinical Oncology ·Xavier Leleu, María‐Victoria Mateos, Sundar Jagannath, Sosana Delimpasi, Maryana Simonova, Ivan Špıčka, Luděk Pour, Iryna Kriachok, Maria Gavriatopoulou, Meletios Α. Dimopoulos, Halyna Pylypenko, Holger W. Auner, Reuben Benjamin, Christopher P. Venner, Mamta Garg, Andrew DeCastro, Jatin J. Shah, Sebastian Grosicki, Paul G. Richardson	2021	4
20	Thromboembolic Risk Reduction and High Rate of Complete Molecular Response with Long-Term Use of Ropeginterferon Alpha-2b in Polycythemia Vera: Results from a Randomized Controlled Study Blood ·Jean‐Jacques Kiladjian, Christoph Klade, Pencho Georgiev, Dorota Krochmalczyk, Liana Gercheva, Miklós Egyed, Viktor Rossiev, Petr Ďulíček, Árpád Illés, Halyna Pylypenko, Lylia Sivcheva, Jiřı́ Mayer, Vera Yablokova, Kurt Krejcy, Hans Carl Hasselbalch, Róbert Královics, Heinz Gisslinger	2019	4

About Halyna Pylypenko

Halyna Pylypenko is a scholar working on Genetics, Oncology, Pathology and Forensic Medicine, Hematology and Rheumatology, having authored 29 papers that have together received 1.3k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (13 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (9 papers), Chronic Lymphocytic Leukemia Research (8 papers), Eosinophilic Disorders and Syndromes (7 papers), Multiple Myeloma Research and Treatments (7 papers), Cytokine Signaling Pathways and Interactions (4 papers), Viral-associated cancers and disorders (4 papers) and Protein Degradation and Inhibitors (3 papers). The work is most often cited by research in Hematology (747 citations), Genetics (389 citations), Oncology (672 citations), Pathology and Forensic Medicine (341 citations) and Molecular Biology (736 citations). Halyna Pylypenko has collaborated with scholars based in Czechia, Poland and United States. Frequent co-authors include Sebastian Grosicki, Helgi van de Velde, Tadeusz Robak, Xavier Leleu, Philippe Moreau, William Deraedt, Bertrand Arnulf, Jean‐Luc Harousseau, Huaibao Feng and James Cavet. Their work appears in journals such as Blood, Journal of Clinical Oncology, Haematologica, HemaSphere and New England Journal of Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact